Company Encyclopedia
View More
name
CTI
300012.SZ
Centre Testing International Group Co. Ltd. provides testing, inspection, certification, calibration, audit, training, and technical services in China and internationally. The company operates in five segments: Trade Protection, Consumer Product Testing, Industrial Testing, Life Sciences, and pharmaceuticals and Medical Services.
250.76 B
300012.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Research and Consulting ServicesIndustry
Industry Ranking1/49
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE13.79%B
    • Profit Margin15.44%A
    • Gross Margin50.24%B
  • Growth ScoreB
    • Revenue YoY7.95%B
    • Net Profit YoY7.70%C
    • Total Assets YoY10.38%B
    • Net Assets YoY11.57%B
  • Cash ScoreC
    • Cash Flow Margin647.65%C
    • OCF YoY7.95%B
  • Operating ScoreB
    • Turnover0.68B
  • Debt ScoreA
    • Gearing Ratio21.08%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CTI plans to launch the fourth employee stock ownership plan, expected to be no more than 5 million shares

    CTI plans to launch the fourth employee stock ownership plan, with a fundraising cap expected to be 71.05 million yuan, repurchasing no more than 5 million shares. The participants include the company's senior management, supervisors, and core business personnel, with a total number not exceeding 600 people. The duration of the plan is 24 months, calculated from the date of approval by the shareholders' meeting, and will automatically terminate if not extended upon expiration

    Zhitong·
    SZ
    300012
    +1.25%
    Zhitong·
    SZ
    300012
    +1.25%

    CTI released its performance for the first three quarters, with a net profit attributable to the parent company of 812 million yuan, an increase of 8.78%

    According to the Zhitong Finance APP, CTI released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 4.702 billion yuan, a year-on-year increase of 6.95%. The net profit attributable to shareholders of the listed company was 812 million yuan, a year-on-year increase of 8.78%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 766 million yuan, a year-on-year increase of 9.26%. The basic earnings per share were 0.4855 yuan

    Zhitong·
    SZ
    300012
    +1.25%
    Zhitong·
    SZ
    300012
    +1.25%

    CTI issued a preliminary profit increase, expecting the net profit attributable to the parent company for the first three quarters to be between 808 million yuan and 818 million yuan, a year-on-year increase of 8.26% to 9.51%

    CTI expects the net profit attributable to shareholders for the first three quarters of 2025 to be between 808 million yuan and 818 million yuan, a year-on-year increase of 8.26% to 9.51%. The net profit after deducting non-recurring gains and losses is expected to be between 762 million yuan and 772 million yuan, a year-on-year increase of 8.72% to 10.04%. The company is promoting steady overall performance improvement by enhancing service quality and increasing innovation, while deepening management and transformation upgrades to strengthen its core competitive advantages

    Zhitong·
    SZ
    300012
    +1.25%
    Zhitong·
    SZ
    300012
    +1.25%

    CTI established a biotechnology company, including animal diagnosis and treatment services

    According to the Qichacha APP, recently, Guangxi Hechi Pinsheng Biotechnology Co., Ltd. was established with a registered capital of 10 million yuan. Its business scope includes: animal diagnosis and treatment; artificial breeding of nationally key protected terrestrial wild animals; artificial breeding of provincially key protected terrestrial wild animals; production of laboratory animals, etc. Qichacha's equity penetration shows that the company is wholly owned by CTI

    Zhitong·
    SZ
    300012
    +1.25%
    Zhitong·
    SZ
    300012
    +1.25%

    CTI released its performance for the first half of the year, with a net profit attributable to the parent company of 467 million yuan, an increase of 7.03%

    CTI released its 2025 semi-annual report, with operating revenue of 2.96 billion yuan, a year-on-year increase of 6.05%; net profit attributable to the parent company of 467 million yuan, a year-on-year increase of 7.03%. Earnings per share are 0.2793 yuan, and it plans to distribute a cash dividend of 0.5 yuan for every 10 shares. The company overcame high base pressure in the second quarter, achieving continuous growth, promoting lean management, exploring AI and digitalization, enhancing operational efficiency, and strengthening organizational capabilities and innovation vitality

    Zhitong·
    SZ
    300012
    +1.25%
    Zhitong·
    SZ
    300012
    +1.25%
    © 2025 Longbridge｜Disclaimer